Mirivadelgat, an Aldehyde Dehydrogenase 2 Activator, in Pulmonary Hypertension Associated With Interstitial Lung Disease
Group 3 Pulmonary Hypertension
Enrolment: 126 · Results not recorded
Loading the evidence…
Drug · No ChEMBL record under the tool-compound name Alda-1 (N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide), an ALDH2 agonist/activator. FLAGGED: the single retained trial tests mirivadelgat (Foresee Pharmaceuticals), a different chemical entity in the same ALDH2-activator class, not Alda-1 itself. This is target-class translation evidence only and should not be read as clinical progression of Alda-1.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Group 3 Pulmonary Hypertension
Enrolment: 126 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Cerulein-induced acute pancreatitis
Alda-1 mediated ALDH2 activation lowered serum pancreatic enzyme levels and the lipid peroxidation products MDA and 4-HNE, decreased Bax and cleaved caspase-3 and increased Bcl-2 both in vivo and in vitro, indicating protection against cerulein-induced acute pancreatitis by mitigating acinar cell a…
Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.